Sree Abirami College of Pharmacy Coimbatore Courses & Fees 2025
Sree Abirami College of Pharmacy Coimbatore Fees & Eligibility
Sree Abirami College of Pharmacy Coimbatore has released the fees for the academic year 2023-2024. Sree Abirami College of Pharmacy Coimbatore UG Fees in year 2023 is Rs 2.4 Lakhs - 3.2 Lakhs. Sree Abirami College of Pharmacy Coimbatore PG Fees in year 2023 is Rs 1.2 Lakhs.
Sree Abirami College of Pharmacy Coimbatore top courses include M.Pharm, Diploma in Pharmacy [D.Pharm], B.Pharm and more. Sree Abirami College of Pharmacy Coimbatore M.Pharm Fees in year 2023 is Rs 1.2 Lakhs, Diploma in Pharmacy [D.Pharm] Fees is Rs 1.1 Lakhs, B.Pharm Fees is Rs 2.4 Lakhs - 3.2 Lakhs for entire course duration.
| Course | Fees | Eligibility | Action |
|---|---|---|---|
M.Pharm 3 Courses | ₹60,000 (1st Year Fees) | Graduation with 55% | |
| ₹55,000 (1st Year Fees) | 10+2 | ||
| ₹80,000 (1st Year Fees) | 10+2 | ||
| ₹80,000 (1st Year Fees) | D.Pharm | ||
| ₹2 Lakhs (1st Year Fees) | 10+2 |
Do you think the Course details are wrong ? Report Here
Courses Offered By Sree Abirami College of Pharmacy Coimbatore 2025
Select Degree and Streams to See Course Fees and Admission Details.
Eligibility:
Eligibility:
Do you think the fees are wrong ? Report Here
Course Finder
Search from 20K+ Courses and 35+ Streams
Popular Streams:
Discover More Colleges
![PSG College of Pharmacy - [PSGCP]](https://assets.collegedunia.com/public/college_data/images/appImage/9760_PSGCP_New.jpg?h=111.44&w=263&mode=stretch)
![Vinayaka Missions College of Pharmacy - [VMCP]](https://assets.collegedunia.com/public/college_data/images/logos/146737189013952321842.png?h=72&w=72&mode=stretch)
![Sankaralingam Bhuvaneswari College Of Pharmacy - [SBCP]](https://assets.collegedunia.com/public/college_data/images/logos/1456912944logo.jpg?h=72&w=72&mode=stretch)
![Arulmigu Kalasalingam College Of Pharmacy - [AKCP]](https://assets.collegedunia.com/public/college_data/images/logos/1605421304Screenshot20201115114254.jpg?h=72&w=72&mode=stretch)
SUBSCRIBE TO OUR NEWS LETTER
Comments